Prevalence of NAT2 polymorphisms and phenotypes associated with the rate of isoniazid biotransformation among Yakutian and Russian tuberculosis patients

To assess the risk of insufficient response or adverse reactions to standard doses of anti-TB drugs, it was proposed to use pharmacogenetic testing of genes of enzymes that metabolize these drugs. Since the frequency of genotypes varies depending on patients’ ethnicity, it is necessary to conduct studies among ethnic groups. The aim of this study was to identify the types of N-acetyltransferase 2 (NAT2) polymorphisms and phenotypes and their prevalence among Yakutian tuberculosis patients, as well as to conduct a comparative analysis with Russian patients. In total 158 patients were examined using real-time PCR: 50 – Yakutians, 41 – Russians (Yakutia), 67 – Russians (Moscow region). Six NAT2 polymorphisms were identified (*5, *6, *7, *11, *12, *13). Significant differences in the distribution of NAT2*5, *11, *12 between Yakutians and Russians were found: these polymorphisms prevail among Russian patients. The frequency of rapid phenotype among Yakutians is higher compared to Russians. The data obtained can contribute to the improvement of the antituberculosis therapy effectiveness in Yakutian patients.

tuberculosis, isoniazid, pharmacogenetics, NAT2, yakutians, russians

1. Global tuberculosis report 2018. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.

2. Treatment of tuberculosis. World Heal. Organ. 2010.

3. Matsumoto T, Ohno M, Azuma J. Future of pharmacogenetics-based therapy for tuberculosis. Pharmacogenomics. 2014;15:601–607. DOI: 10.2217/pgs.14.38

4. Wang P, Pradhan K, Zhong X, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm. Sin. B. 2016;6(5):384-392.

5. Cai Y, Yi JY, Zhou CH, Shen XZ. Pharmacogenetic Study of DrugMetabolising Enzyme Polymorphisms on the Risk of Anti-Tuberculosis Drug-Induced Liver Injury: A Meta-Analysis. PLoS One. 2012;7(10):1–8.

6. Zhang M, et al. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 2018;84(12):2747–2760.

7. Mahto H, et al. Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence metaanalysis as evidence. Biosci. Rep. 2018;39(1): BSR20180845.

8. Wang PY, Xie SY, Hao Q, et al. Jiang. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: A meta-analysis. Int. J. Tuberc. Lung Dis. 2012;16(5):589–595.

9. Shi J, Xie M, Wang J, et al. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis. Pharmacogenomics. 2015;16:2083–2097.

10. Donald PR, et al. The Influence of Human N-Acetyltransferase Genotype on the Early Bactericidal Activity of Isoniazid. Clin. Infect. Dis. Publushed by Oxford Univ. Press. 2004;39(10): 1425–1430.

11. Weiner M, et al. Low Isoniazid Concentrations and Outcome of Tuberculosis Treatment with Once-Weekly Isoniazid and Rifapentine. Am. J. Respir. Crit. Care Med. 2003;167:1341–1347.

12. Kinzig-schippers M, et al. Should We Use N-Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses? Society. 2005;49(5):1733–1738.

13. Hasunuma T, Azuma J, Ohno M, et al. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2. Eur. J. Clin. Pharmacol. 2007;63(10):927–933.

14. Azuma J, Ohno M, Kubota R. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis : A randomized controlled trial for pharmacogenetics-based therapy. Pharmacogenetics. 2013; 1091–1101.

15. Zhu R, et al. The Pharmacogenetics of NAT2 Enzyme Maturation in Perinatally HIV Exposed Infants Receiving Isoniazid. J Clin Pharmacol. 2009;6(11):1249–1254.

16. Jagodziński J, et al. Correlation of N-Acetyltransferase 2 Genotype with Isoniazid Acetylation in Polish Tuberculosis Patients. Biomed Res. Int. 2013;2013(Figure 1):1–5.

17. Ministry of health of the Republic of Sakha (Yakutia) GBU «Republican children’s tuberculosis sanatorium named after T. P. Dmitrieva». Statistical report for 2018. (In Russ).

18. Diallo I, Vangenot C, Sanchez-mazas A, et al. Variation in NAT2 acetylation phenotypes is associated with differences in food-producing subsistence modes and ecoregions in Africa. BMC Evol. Biol. 2015;1–20.

19. Toure A, et al. Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients. Toxicol. Reports. 2016;3:826–831.

20. Mortensen HM, et al. Characterization of genetic variation and natural selection at the arylamine N-acetyltransferase genes in global human populations. Pharmacogenomics. 2015;12(11):1545–1558.

21. Tang H, et al. Genetic Structure , Self-Identified Race. Ethnicity, and Confounding in Case-Control Association Studies. 2005;268–275.

22. Sabbagh A, Darlu P, Crouau-roy B, Poloni ES. Arylamine N-Acetyltransferase 2 (NAT2) Genetic Diversity and Traditional Subsistence: A Worldwide Population Survey. PLoS One. 2011; 6(4):e18507. DOI: 10.1371/journal.pone.0018507

23. Hein DW. N-acetyltransferase 2 genetic polymorphism : effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene. 2006;2:1649–1658.

24. Kurose K, Sugiyama E, Saito Y. Population Differences in Major Functional Polymorphisms of Pharmacokinetics / pharmacodynamics-related Genes in Eastern Asians and Europeans : Implications in the Clinical Trials for Novel Drug Development. Drug metabolism and pharmacokinetics. 2012;27(1):1–18.

25. Gra O, et al. Microarray-Based Detection of CYP1A1, CYP2C9, CYP2C19, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, NAT2, HLA-DQA1, and AB0 Allele Frequencies in Native Russians. Genet. Test. Mol. Biomarkers. 2010;14(3):329–342.